Summary of Package Insert 1

Similar documents
Billing and Coding Guide. Hospital Outpatient Department

SAMPLE CLAIM FORMS FOR SPINRAZA

Summary of Package Insert 1 for PuraPly Wound Matrix

Supplementary Online Content

Summary of Package Insert 1 for PuraPly Antimicrobial Wound Matrix

Cahaba Medicare Policy Primer 1,2 for Apligraf

Palmetto Medicare Policy Primer

Oregon Individual and Family Plans OREGON APPLICATION AND STANDARD HEALTH STATEMENT

Novitas Medicare Policy Primer

Bright Futures Medical Screening Reference Table 2 to 5 Day (First Week) Visit

WPS Medicare Policy Primer

CODING AND REIMBURSEMENT GUIDE

CGS Medicare Policy Primer

Clinical Study Report Synopsis Drug Substance Naloxegol Study Code D3820C00018 Edition Number 1 Date 01 February 2013 EudraCT Number

PNEUMOVAX 23 is recommended by the CDC for all your appropriate adult patients at increased risk for pneumococcal disease 1,2 :

Using Paclobutrazol to Suppress Inflorescence Height of Potted Phalaenopsis Orchids

Impact of Pharmacist Intervention on Diabetes Patients in an Ambulatory Setting

First Coast Service Options (FCSO) Medicare Policy Primer

Patient Identification. a Yes. a No. Patient: First. Last. Address: Street. Apt. State. City. Zip. Date of Birth: Weight: Age: Race:

Community. Profile Powell County. Public Health and Safety Division

Community. Profile Big Horn County. Public Health and Safety Division

Community. Profile Yellowstone County. Public Health and Safety Division

Community. Profile Lewis & Clark County. Public Health and Safety Division

Community. Profile Missoula County. Public Health and Safety Division

Community. Profile Anaconda- Deer Lodge County. Public Health and Safety Division

Invasive Pneumococcal Disease Quarterly Report July September 2018

Computer-Aided Learning in Insulin Pump Training

XII. HIV/AIDS. Knowledge about HIV Transmission and Misconceptions about HIV

Coding for Wound Care

Invasive Pneumococcal Disease Quarterly Report. July September 2017

SUSPECT ADVERSE REACTION REPORT

Community. Profile Carter County. Public Health and Safety Division

Pressure Ulcers ecourse: Module 2 Quiz II

Seasonal influenza vaccination programme country profile: Ireland

Topical Oxygen Wound Therapy (MEDICAID)

Diabetes affects 29 million Americans, imposing a substantial

Supplementary Online Content

Assessment of Depression in Multiple Sclerosis. Validity of Including Somatic Items on the Beck Depression Inventory II

METHOD 4010 SCREENING FOR PENTACHLOROPHENOL BY IMMUNOASSAY

5 WAYS VCARE? What is GLAUCOMA. has earned the highest MEDICAID? Are you on. Are you at Risk? Viva Medicare Plus. to Avoid Hospital Readmissions

Utilization of dental services in Southern China. Lo, ECM; Lin, HC; Wang, ZJ; Wong, MCM; Schwarz, E

BENIGN ulceration along the greater curvature of the pars media of the

Effect on Glycemic, Blood Pressure, and Lipid Control according to Education Types

Welcome to our Practice

DermACELL AWM Comprehensive Reimbursement Resource Guide. Prepared by Musculoskeletal Clinical Regulatory Advisers, LLC. Version 01/2018.

Vitamin D and Mushrooms: Enrichment With Pulsed UV Light. Michael Kalaras Department of Food Science The Pennsylvania State University

Original Article. T Akter 1, N Islam 2, MA Hoque 3, S Khanam 4, HA khan 5, BK Saha 6. Abstract:

Whangarei District Council Class 4 Gambling Venue Policy

WHEN PRECISE PLACEMENT IS CRITICAL

Safety and Tolerability of Subcutaneous Sarilumab and Intravenous Tocilizumab in Patients With RA

Urinary Tract Infection in Women

Surgical Preparation Codes for Skin Replacement Surgery** Hospital Outpatient/Ambulatory Surgical Center Setting

Urinary Tract Infection in Men

Chronic obstructive pulmonary disease (COPD) is the third

Target: 10 mg/day within several days Schizophrenia in adolescents (2.1)

The Effects of Small Sized Rice Bowl on Carbohydrate Intake and Dietary Patterns in Women with Type 2 Diabetes

Clinical Policy: EpiFix Wound Treatment

Aetna Health Management HMO Products SouthEast Region (Including Arkansas) Medical and Non-Medical Approvals and Denials from 01/01/2018 to 03/31/2018

The Quality and Outcomes Framework (QOF) is a pay-for-performance

Wound & Burn. Reimbursement & Coding Guide

SYNOPSIS Final Abbreviated Clinical Study Report for Study CA ABBREVIATED REPORT

β-hydroxybutirate Levels as a Determinant for The Success of Diabetic Ketoacidosis Management

Multiple sclerosis (MS) affects approximately. Triaging Patients with Multiple Sclerosis in the Emergency Department. Room for Improvement

build Firm, sexy arms

CLPNA Pressure Ulcers ecourse: Module 5.3 Quiz I page 1

Input from external experts and manufacturer on the 2 nd draft project plan Stool DNA testing for early detection of colorectal cancer

8/1/2017. Correlating Radiomics Information with Clinical Outcomes for Lung SBRT. Disclosure. Acknowledgements

Aetna Health Management HMO Products SouthEast Region (Including Arkansas) Medical and Non-Medical Approvals and Denials from 01/01/2017 to 03/31/2017

Trends in antihypertensive and lipidlowering therapy in subjects with type II diabetes: clinical effectiveness or clinical discretion?

Efficacy of Sonidegib in Patients With Metastatic BCC (mbcc)

This is a controlled document. The master document is posted on the JRCO website and any print-off of this document will be classed as uncontrolled.

C reactive protein: an aid to assessment and

Summary. Effect evaluation of the Rehabilitation of Drug-Addicted Offenders Act (SOV)

phosphatase isoenzyme activity: estimation of

A Four-System Comparison of Patients With Chronic Illness: The Military Health System, Veterans Health Administration, Medicaid, and Commercial Plans

A survey of atrial fibrillation in general practice: the West Birmingham Atrial Fibrillation Project

Appendix J Environmental Justice Populations

A cross-sectional and follow-up study of leukopenia in tuberculosis patients: prevalence, risk factors and impact of anti-tuberculosis

Introduction. These patients benefit less from conventional chemotherapy than patients identified as MMR proficient or microsatellite stable 3-5

Review TEACHING FOR GENERALIZATION & MAINTENANCE

key words: chronic obstructive pulmonary disease, beta agonists, Medicare, health care costs, health care utilization

Opioid Use and Survival at the End of Life: A Survey of a Hospice Population

T.S. Kurki a, *,U.Häkkinen b, J. Lauharanta c,j.rämö d, M. Leijala c

TAKE CONTROL HIGH LEVEL

Finite-Dimensional Linear Algebra Errata for the first printing

CheckMate 153: Randomized Results of Continuous vs 1-Year Fixed-Duration Nivolumab in Patients With Advanced Non-Small Cell Lung Cancer

ORIGINAL ARTICLE. Diagnostic Signs of Accommodative Insufficiency. PILAR CACHO, OD, ÁNGEL GARCÍA, OD, FRANCISCO LARA, OD, and M A MAR SEGUÍ, OD

Patient Survival After Surgical Treatment of Rectal Cancer

Agilent G6825AA MassHunter Pathways to PCDL Software Quick Start Guide

THE 2017 GENENTECH ONCOLOGY TREND REPORT

EFFECTS OF INGREDIENT AND WHOLE DIET IRRADIATION ON NURSERY PIG PERFORMANCE

of comorbid conditions, interventions Diagnosis and treatment, treatment reduction of risk factors for CVD to slow disease progression,

Soybean Hulls as an Alternative Feed for Horses

Original Article INTRODUCTION. Korean Diabetes J 2010;34: doi: /kdj pissn eissn

Rising costs have led to a number of federal initiatives to

Anemia in pediatric hemodialysis patients: Results from the 2001 ESRD Clinical Performance Measures Project

Reducing the Risk. Logic Model

Presented at the 75 th Annual Meeting of the American Academy of Dermatology, Orlando, FL, March 3-7, 2017 METHODS INTRODUCTION OBJECTIVE

Transcription:

Summry of Pckge Insert 1 For Sttes with Non-Published Policies Indictions Non-infected prtil nd full-thickness skin ulcers due to VSU 2 of greter thn 1 month durtion nd which hve not dequtely responded to conventionl ulcer therpy. Full-thickness neuropthic DFU 3 of greter thn 3 weeks durtion which hve not dequtely responded to conventionl ulcer therpy nd which extend through the dermis but without tendon, muscle, cpsule or bone exposure. Limittions The sfety nd effectiveness of pligrf hve not been estblished for ptients receiving greter thn 5 device pplictions. oding PT/HPS 1,4 Q4101: pligrf, per squre centimeter For Plmetto G, J modifier must be billed in conjunction with Q4101 long with JW modifier for wstge ppliction odes for Leg 15271: ppliction of skin substitute grft to trunk, rms, legs, totl wound surfce re up to 100 sq cm; first 25 sq cm or less wound surfce re 15272: ppliction of skin substitute grft to trunk, rms, legs, totl wound surfce re up to 100 sq cm; ech dditionl 25 sq cm wound surfce re, or prt thereof (List seprtely in ddition to code for primry procedure) 15273: ppliction of skin substitute grft to trunk, rms, legs, totl wound surfce re greter thn or equl to 100 sq cm; first 100 sq cm wound surfce re 15274: ppliction of skin substitute grft to trunk, rms, legs, totl wound surfce re greter thn or equl to 100 sq cm; ech dditionl 100 sq cm wound surfce re, or prt therof (List seprtely in ddition to code for primry procedure) ppliction odes for Foot 15275: ppliction of skin substitute grft to fce, sclp, eyelids, mouth, neck, ers, orbits, genitli, hnds, feet, nd/or multiple digits, totl wound surfce re up to 100 sq cm; first 25 sq cm or less wound surfce re 15276: ppliction of skin substitute grft to fce, sclp, eyelids, mouth, neck, ers, orbits, genitli, hnds, feet, nd/or multiple digits, totl wound surfce re up to 100 sq cm; ech dditionl 25 sq cm wound surfce re, or prt thereof (List seprtely in ddition to code for primry procedure) 15277: ppliction of skin substitute grft to fce, sclp, eyelids, mouth, neck, ers, orbits, genitli, hnds, feet, nd/or multiple digits, totl wound surfce re greter thn or equl to 100 sq cm; first 100 sq cm wound surfce re 15278: ppliction of skin substitute grft to fce, sclp, eyelids, mouth, neck, ers, orbits, genitli, hnds, feet, nd/or multiple digits, totl wound surfce re greter thn or equl to 100 sq cm; ech dditionl 100 sq cm wound surfce re, or prt therof (List seprtely in ddition to code for primry procedure) 1 This document is for informtionl purposes only. Use of this informtion does not gurntee coverge or pyment for these services by Medicre or other pyors. Physicins nd other providers should use independent judgment when selecting codes tht most ppropritely describe the services provided to ptient. Physicins nd hospitls re solely responsible for complince with Medicre nd other pyors lws, rules, nd requirements. 2 VSU = Venous Stsis Ulcer. 3 DFU = Dibetic Foot Ulcer. 4 PT mericn Medicl ssocition. ll Rights Reserved. www.pligrf.com 1.888.HEL.2.DY (888-432-5232) pligrf is registered trdemrk of Novrtis 2012 Orgnogenesis, Inc.

nytown Hospitl 123 Medicl Drive nytown, NJ 00000 1 2 3 PT. 4 TYPE NTL # HI 012345678 OF ILL b. MED. RE. # 5 FED. T NO. 6 STTEMENT OVERS PERIOD FROM THROUGH 8 PTIENT NME 9 PTIENT DDRESS b b c d 10 IRTHDTE 11 SE DMISSION ONDITION ODES 12 DTE 13 HR 14 TYPE 15 SR 16 DHR 29 DT 30 17 STT 18 19 20 21 22 23 24 25 26 27 28 STTE 01011935 F 2012 No Forml Policy PI pligrf Smple U-04 lim Form 01-2345678 01012012 01012012 111 Mple venue nytown NJ 00000 31 OURRENE 32 OURRENE 33 OURRENE 34 OURRENE 35 OURRENE SPN 36 OURRENE SPN 37 ODE DTE ODE DTE ODE DTE ODE DTE ODE FROM THROUGH ODE FROM THROUGH 7 131 e b ll dtes 38 39 VLUE ODES 40 VLUE ODES 41 VLUE ODES should be in ODE MOUNT ODE MOUNT ODE MOUNT eight digit Jne Smith formt. 111 Mple venue b nytown, NJ 00000 c d b 1 2 3 4 42 REV. D. 43 DESRIPTION 44 HPS / RTE / HIPPS ODE 45 SERV. DTE 46 SERV. UNITS 47 TOTL HRGES 48 NON-OVERED HRGES 49 636 pligrf Q4101 01012012 44 360 ppliction, first 25 sq cm 15271 01012012 1 360 ppliction, ech dditionl 25 sq cm 15272 01012012 1 1 2 3 4 5 5 6 7 8 9 10 11 12 13 14 Enter pproprite revenue codes for ll services provided. Revenue code 636 should be used when billing for pligrf. 15271 nd 15272 should be used bsed on the size of the wound. For exmple, LEG wound mesuring 30 sq cm, would be billed using 15271 (first 25 sq cm or less) nd 15272 (dditionl 25 sq cm or prt thereof). pligrf is supplied in 44 units. 6 7 8 9 10 11 12 13 14 15 15 16 16 17 17 18 18 19 19 20 20 21 21 22 22 23 PGE OF RETION DTE TOTLS 23 50 PYER NME Medicre 51 HELTH PLN ID 987654 52 REL. INFO 53 SG. 54 PRIOR PYMENTS 55 EST. MOUNT DUE 56 NPI EN. 57 OTHER PRV ID 58 INSURED S NME 59 P. REL 60 INSURED S UNIQUE ID 61 GROUP NME 62 INSURNE GROUP NO. 63 TRETMENT UTHORIZTION ODES 64 DOUMENT ONTROL NUMER 65 EMPLOYER NME 66 D xxx.xx 67 Plese refer to odes ommonly Used when illing for pligrf forpproprite ID-9-M dignosis D E F G H codes nd your specific pyer s requirements. I J K L M N O P Q 69 DMIT 70 PTIENT 71 PPS 72 73 D RESON D b c ODE EI b c 74 PRINIPL PROEDURE. OTHER PROEDURE b. OTHER PROEDURE 75 ODE DTE ODE DTE ODE DTE 76 TTENDING NPI QUL LST FIRST c. OTHER PROEDURE d. OTHER PROEDURE e. OTHER PROEDURE ODE DTE ODE DTE ODE DTE 77 OPERTING NPI QUL LST FIRST 80 REMRKS 81 78 OTHER NPI QUL b LST FIRST 68 c 79 OTHER NPI QUL U-04 MS-1450 PPROVED OM NO. 0938-0997 d LST FIRST Ntionl Uniform NU illing ommittee THE ERTIFITIONS ON THE REVERSE PPLY TO THIS ILL ND RE MDE PRT HEREOF.

2012 No Forml Policy PI pligrf Smple MS-1500 lim Form Physicin Services in n Outptient Setting 123-45-6789 12 13 35 123 ny Street 123 ny Street NYTOWN NJ NYTOWN NJ 00000 (973) 555-1234 00000 973 555-1234 SIGNTURE ON FILE xxx xx xxx xx Plese refer to odes ommonly Used when illing for pligrf for pproprite ID-9-M dignosis codes nd your specific pyer s requirements. 01 01 12 01 01 12 22 01 01 12 01 01 12 22 15271 15272 15271 nd 15272 should be used bsed on the size of the wound. For exmple, LEG wound mesuring 30 sq cm, would be billed using 15271 (first 25 sq cm or less) nd 15272 (dditionl 25 sq cm or prt thereof). 01-2345678 012345678

2012 No Forml Policy PI pligrf Smple MS-1500 lim Form Physicin Services in n Office Setting 123-45-6789 12 13 35 123 ny Street 123 ny Street NYTOWN NJ NYTOWN NJ 00000 (973) 555-1234 00000 973 555-1234 SIGNTURE ON FILE xxx xx xxx xx Plese refer to odes ommonly Used when illing for pligrf for pproprite ID-9-M dignosis codes nd your specific pyer s requirements. 01 01 12 01 01 12 11 Q4101 44 01 01 12 01 01 12 11 01 01 12 01 01 12 11 15271 15272 pligrf is supplied in 44 units. 15271 nd 15272 should be used bsed on the size of the wound. For exmple, LEG wound mesuring 30 sq cm, would be billed using 15271 (first 25 sq cm or less) nd 15272 (dditionl 25 sq cm or prt thereof). 01-2345678 012345678

Model Documenttion Form for No Forml Policy / Summry of Pckge Insert Pretretment: 1. Durtion of ulcer (DFU: 3 weeks, VSU: greter thn 1 month) weeks 2. Document filure to respond to conservtive mesures ( filed response is defined s n ulcer tht hs incresed in size or depth nd no indiction tht improvement is likely e.g., epithelil in growth nd progression towrds closure) 3. Document mesurement of the ulcer t bseline, following cesstion of conservtive mngement. 4. Describe dequte tretment of the underlying disese process contributing to the ulcer 5. Dignosis of ptient VSU: 454.0, 454.1, 454.2, 459.11, 459.13, 459.31, 459.33, 459.81 DFU: 707.10-707.15, 707.19, 249.00-249.01, 249.10-249.11, 249.20-249.21, 249.30-249.31, 249.40-249.41, 249.50-254.951, 249.60-249.61, 249.70-249.71, 249.80-249.81, 250.60-250.63, 250.70-250.73, 250.80-250.83 6. Document tht wound is free of infection, redness, dringe, underlying osteomyelitis, surrounding cellulitis, tunnels nd trcts, eschr or ny necrotic mteril 7. For DFU, document current Hb1 reding (Hb1 should not exceed 12%) 8. Document dequte rteril blood supply s evidenced by n I of 0.65 or greter ontinued on next pge > This document is for informtionl purposes only. Use of this informtion does not gurntee coverge or pyment for these services by Medicre or other pyors. LDs re updted by Medicre nd Medicre contrctors on regulr bsis. Physicins nd other providers should regulrly refer to the pplicble Medicre locl coverge determintions (LDs) for complete informtion on medicl necessity documenttion requirements. Physicins, providers nd hospitls re solely responsible for complince with Medicre nd other pyors lws, rules, nd requirements. pligrf is registered trdemrk of Novrtis 2010 Orgnogenesis, Inc.

Tretment: 9. Document mesurement of ulcer (width nd length or circumference nd depth) immeditely prior to ppliction of pligrf sq cm 10. Document whether this is n initil ppliction of pligrf or reppliction. (pligrf is limited to 5 pplictions per ulcer) 11. For pligrf repplictions, document tht pplictions hve been successful (e.g. decrese in size or depth, increse in grnultion tissue) 12. Document the wound dressing chnges nd the stndrd conservtive mesures ccompnying the wound tretment with pligrf 13. Document how the wound site ws prepred, nd how pligrf ws fixted on the wound This document is for informtionl purposes only. Use of this informtion does not gurntee coverge or pyment for these services by Medicre or other pyors. LDs re updted by Medicre nd Medicre contrctors on regulr bsis. Physicins nd other providers should regulrly refer to the pplicble Medicre locl coverge determintions (LDs) for complete informtion on medicl necessity documenttion requirements. Physicins, providers nd hospitls re solely responsible for complince with Medicre nd other pyors lws, rules, nd requirements. pligrf is registered trdemrk of Novrtis 2010 Orgnogenesis, Inc.

ID-9 M odes commonly used when billing for pligrf 1 454.0 Vricose veins of lower extremities, with ulcer 454.1 Vricose veins of lower extremities, with inflmmtion 454.2 Vricose veins of lower extremities, with ulcer nd inflmmtion 459.11 Postphlebitic syndrome with ulcer 459.13 Postphlebitic syndrome with ulcer nd inflmmtion 459.31 hronic venous hypertension with ulcer 459.33 hronic venous hypertension with ulcer nd inflmmtion 459.81 Other specified disorders of circultory system, venous (peripherl) insufficiency, unspecified 707.10 Ulcer of lower limb, unspecified 707.11 Ulcer of thigh 707.12 Ulcer of clf 707.13 Ulcer of nkle 707.14 Ulcer of heel nd midfoot (Plntr surfce of midfoot) 707.15 Ulcer of other prt of foot (Toes) 707.19 Ulcer of other prt of lower limb 707.8 hronic ulcer of other specified sites 249.00 Secondry dibetes mellitus without mention of compliction, not stted s uncontrolled, 249.01 Secondry dibetes mellitus without mention of compliction, uncontrolled 249.10 Secondry dibetes mellitus with ketocidosis, not stted s uncontrolled, 249.11 Secondry dibetes mellitus with ketocidosis, uncontrolled 249.20 Secondry dibetes mellitus with hyperosmolrity, not stted s uncontrolled, 249.21 Secondry dibetes mellitus with hyperosmolrity, uncontrolled 249.30 Secondry dibetes mellitus with other com, not stted s uncontrolled, 249.31 Secondry dibetes mellitus with other com, uncontrolled ontinued on next pge > pligrf is registered trdemrk of Novrtis 2010 Orgnogenesis, Inc.

249.40 Secondry dibetes mellitus with renl mnifesttions, not stted s uncontrolled, 249.41 Secondry dibetes mellitus with renl mnifesttions, uncontrolled 249.50 Secondry dibetes mellitus with ophthlmic mnifesttions, not stted s uncontrolled, 249.51 Secondry dibetes mellitus with ophthlmic mnifesttions, uncontrolled 249.60 Secondry dibetes mellitus with neurologicl mnifesttions, not stted s uncontrolled, 249.61 Secondry dibetes mellitus with neurologicl mnifesttions, uncontrolled 249.70 Secondry dibetes mellitus with peripherl circultory disorders, not stted s uncontrolled, 249.71 Secondry dibetes mellitus with peripherl circultory disorders, uncontrolled 249.80 Secondry dibetes mellitus with other specified mnifesttions, not stted s uncontrolled, 249.81 Secondry dibetes mellitus with other specified mnifesttions, uncontrolled 249.90 Secondry dibetes mellitus with unspecified compliction, not stted s uncontrolled, 249.91 Secondry dibetes mellitus with unspecified compliction, uncontrolled 250.60 Dibetes With Neurologicl Mnifesttions, Type II Or Unspecified Type, not stted s uncontrolled 250.61 Dibetes With Neurologicl Mnifesttions, Type I (Juvenile Type), not stted s uncontrolled 250.62 Dibetes With Neurologicl Mnifesttions, Type II Or Unspecified Type, uncontrolled 250.63 Dibetes With Neurologicl Mnifesttions, Type I (Juvenile Type), uncontrolled 250.70 Dibetes With Peripherl ircultory Disorders, Type II Or Unspecified type, not stted s uncontrolled 250.71 Dibetes With Peripherl ircultory Disorders, Type I (Juvenile Type), not stted s uncontrolled 250.72 Dibetes With Peripherl ircultory Disorders, Type II Or Unspecified type, uncontrolled 250.73 Dibetes With Peripherl ircultory Disorders, Type I (Juvenile Type), uncontrolled 250.80 Dibetes with other specified mnifesttions, type II type, not stted s uncontrolled 250.81 Dibetes with other specified mnifesttions, type I, not stted s uncontrolled 250.82 Dibetes with other specified mnifesttions, type II type, uncontrolled 250.83 Dibetes with other specified mnifesttions, type I, uncontrolled 1 This brief summry is provided for considertion only. ll codes provided herein re for informtion purposes only nd shll not be construed s sttement, promise, or gurntee tht these codes re ccurte or reimbursement will be received. oding requirements re subject to chnge t ny time, therefore check with your locl pyer regulrly to verify prior uthoriztion requirements. pligrf is registered trdemrk of Novrtis 2010 Orgnogenesis, Inc.